Healthy Volunteer
Conditions
Keywords
Drug interaction, Rosuvastatin, Telmisartan, Pharmacokinetic, (Pharmacokinetics and Drug Interaction)
Brief summary
This clinical trial is designed to compare the pharmacokinetic characteristics of combination and separate administration of Crestor(Rosuvastatin) and Micardis(Telmisartan). Also investigate drug interaction between separate and combination administration. Total number of subjects is 48. 4 group(12 for 1 group), 2 period, consecutive 6 day administration, 16 days washout after 6th day of administration. The subjects of Part 1 take Crestor alone and Crestor+Micardis combination by a cross-over design during 2 each period. The other subjects of Part 2 take Micardis alone and Crestor+Micardis combination by a cross-over design during 2 each period.
Interventions
DRUGCrestor 20mg(Rosuvastatin 20mg), Micardis 80mg(Telmisartan 80mg)
For co-administration, Crestor 1 tablet and Micardis 1 tablet a day for 6 days in each period. For separate administration, Crestor 1 tablet a day for 6 days and Micardis 1 tablet a day for 6 days in each period.
Sponsors
Yuhan Corporation
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
1. Healthy male and female aged 20 to 50 with a body mass index(BMI) between 19 and 27 kg/m2 2. Acceptable medical history, physical examination, laboratory tests and EKG, during screening 3. Provision of signed written informed consent •20\ 50 yrs old, healthy Korean Subjects
Exclusion criteria
1.History of and clinically significant disease 2.Sitting blood pressure meeting the following criteria at screening: 150 ≤ systolic blood pressure ≤90 (mmHg) and 95 ≤ diastolic blood pressure ≤ 50 (mmHg) amd 100 ≤ Heart rate ≤ 40 3. A history of drug abuse or the presence of positive reactions to drugs that have abuse potential in urine screenings for drugs. 4\. Administration of other investigational products within 90 days prior to the first dosing. 5\. Administration of herbal medicine within 30 days or administration of ethical drugs within 14 days or administration of over-the-counter (OTC) drugs within 7 days prior to the first dosing of the investigational product (if the investigator (study doctor) determines that the person meets other criteria appropriately, the relevant person may participate in the study). 6.Have AST(SGOT) or/and ALT(SGPT) \> 3 times of normal upper limit at the time of screening 7. Volunteers considered not eligible for the clinical trial by the investigator (study doctor) due to reasons including laboratory test results, ECGs, or vital signs.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| AUC | 72hr | AUC τ,ss of Rosuvastatin and Telmisartan |
| Cmax | 72hr | Cmax,ss of Rosuvastatin and Telmisartan |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| t1/2 | 72hr | t1/2 of Rosuvastatin, N-desmetyl Rosuvastatin and Telmisartan |
| AUC | 72hr | AUC last,ss of Rosuvastatin, N-desmetyl Rosuvastatin and Telmisartan |
| Cmax | 72hr | Cmax,ss of N-desmetyl Rosuvastatin |
| Cmin | 72hr | Cmin,ss of Rosuvastatin, N-desmetyl Rosuvastatin and Telmisartan |
| Tmax | 72hr | Tmax,ss of Rosuvastatin, N-desmetyl Rosuvastatin and Telmisartan |
Countries
South Korea
Outcome results
None listed